{"id":"NCT02116803","sponsor":"Novartis Pharmaceuticals","briefTitle":"An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective","officialTitle":"An Open Label, Multi-center, Extension Study to Evaluate Long-term Safety and Tolerability of Dovitinib in Patients With Solid Tumors, Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored, Single Agent Dovitinib Studies, Which Have Fulfilled the Requirements for the Primary Objective, and Are Benefitting From Continued Dovitinib Treatment as Assessed by the Investigator","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2014-05-28","primaryCompletion":"2016-11-28","completion":"2016-11-28","firstPosted":"2014-04-17","resultsPosted":"2018-02-01","lastUpdate":"2018-03-01"},"enrollment":12,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Solid Tumors"],"interventions":[{"type":"DRUG","name":"dovitinib","otherNames":["TKI258"]},{"type":"DRUG","name":"fulvestrant","otherNames":[]}],"arms":[{"label":"dovitinib","type":"EXPERIMENTAL"},{"label":"dovitinib + fulvestrant","type":"EXPERIMENTAL"}],"summary":"The study allowed continued safety follow-up of patients who were on single agent dovitinib or dovitinib in combination with fulvestrant treatment in a Novartis-sponsored study which had met its primary endpoint and were benefiting from the treatment as judged by the investigator.","primaryOutcome":{"measure":"Number of Participants With Adverse Events of Grades 3 and 4 Severity","timeFrame":"Until the last patient discontinued dovitinib up to 30 months","effectByArm":[{"arm":"Dovitinib","deltaMin":6,"sd":null},{"arm":"Dovitinib + Fulvestrant","deltaMin":2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":9,"countries":["United States","Austria","Belgium","Denmark","Italy","Japan","Spain"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":10},"commonTop":["DECREASED APPETITE","DIARRHOEA","ANGINA PECTORIS","CONSTIPATION","FATIGUE"]}}